tbuckley/cabot-search huggingface dataset:
AB0620 Sexual Functioning and Quality of Life among Married Women with Systemic Sclerosis
Authors: F. Frikha, J. Masmoudi, Z. Bahloul
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Sexuality is an often neglected area in patients with rheumatic disease. <h3>Objectives</h3> The aim of this study is to assess sexual functioning and quality of life in a group of married women with Systemic Sclerosis (SSc). <h3>Methods</h3> This is a horizontal study for descriptive and analytical purposes. Married women with SSc were interviewed about their sexual functioning and their quality of life. <h3>Results</h3> A total of ten patients who met the criteria have accepted to participate to the study. Their mean age was 52, 4±8,2 years. Eight women thought that the disease had affected their sexual activity. All patients reported a decrease in the frequency of intercourse since the onset of their disease. Eight of the sample reported a diminished desire for a sexual relationship. The reasons were fatigue, altered body image and pain. The assessment of sexual functioning using the Female sexual function index (FSFI) showed a mean FSFI score at 14,2±7,8 with nine women scoring in the range associated with sexual dysfunction (SD) (&lt;26). All the subscales were affected. Our patients reported a mean total score on WHOQOL-brief (World Health Quality of Life-Brief Version) of 60 out of 120 indicating a moderate altered quality of life. Depression has been identified as determinants of impaired sexual function. <h3>Conclusions</h3> The prevalence of SD in women with SSc is high when a specific questionnaire is used to assess it. These results indicate that in daily practice, inquiring about sexuality and screening for depressive symptoms is indicated for every patient with SSc. <h3>References</h3> Impens AJ, Seibold JR. Vascular Alterations and Sexual Function in Systemic Sclerosis International Journal of Rheumatology 2010; 2010:139020. Knafo R, Thombs BD, Jewett LR, Hudson M, Wigley F, Haythonthwaite JA. (Not) talking about sex: a systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. Rheumatology 2009;48:1300-3. Knafo R, Haythornthwaite JA, Heinberg L, Wigley FM, Thombs BD. The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis. Rheumatology (Oxford). 2011; 50 (6):1125-30. Levis B, Hudson M, Knafo R, et al. Canadian Scleroderma Research Group (CSRG). Rates and correlates of sexual activity and impairment among women with systemic sclerosis. Arthritis Care Res (Hoboken). 2012;64(3):340-50. Guerriere JA, Rosen RC, Seibold JR. Quality of life and sexual function in women with systemic sclerosis (SSc). Arthritis Rheum 2001; 44 Suppl: S328. <h3>Acknowledgements</h3> We would like to thank all the participants. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2985
Abstract 3679: Preliminary results from a patient group, excluded from the National Lung Cancer Screening Trial, who are at high risk for lung cancer- heavy smokers with HIV
Authors: Alicia Hulbert, Craig Hooker, Travis Brown, Karen Horton, John Wrangle, Elliott Fishman, Kristen Pelosky, Beverley Lee, James Shin, Marian Rutlege, Celis Sam, Genevieve Pridham, Sue Lee, Eli Luong, Yvonne Carter, Robert Brown, James Herman, Malcolm Brock
Journal: Cancer Research (2011)

Abstract Purpose: Within the HIV population, the incidence of lung cancer is estimated to be 2-4 times that of the general population. Of the non AIDS associated malignancies, lung cancer is the leading cause of death among HIV patients who develop malignancy because of its advanced stage of presentation. The National Lung Cancer Screening Trial recently reported a 20% reduction in mortality for patients undergoing low dose computed tomography (CT) screening, but individuals with HIV diagnosis were excluded. To report the results of an observational pilot study of lung cancer CT screening in a cohort of HIV heavy smokers. Materials and Methods: A prospective cohort study was performed with 185 asymptomatic individuals with confirmed HIV diagnosis who had smoked 20 pack-years or more. All participants had baseline (prevalence) chest CT scanning and 107 patients (58.2%) also received at least one subsequent annual (incidence) examination of the chest and upper abdomen. All patients underwent hand held spirometry testing, cytologic analysis of sputa, and detailed health status questioning. Results: Of the 185 individuals, there were 31.4% females, 68.6% males, 90.3% African-Americans, 8.7% Caucasian, and 1.1% Hispanic. The median age at enrolment was 48 years, and the median number of smoking pack-years was 34. Non-calcified nodules were detected in 4 participants (2.1%) by low-dose prevalent CT compared to no nodules on incident CT scans. Only one patient with malignancy was detected (0.54%) on prevalent scanning and none on incident scanning. Stage of malignancy was advanced. No biopsies were undertaken for benign disease. CT evidence of COPD and coronary artery disease were present in 24% and 27% of patients, respectively. Additional CT findings of clinical importance were noted in the chest in 132 (71.7%) patients and extrathoracically in 30 (16.3%) of patients, respectively. Conclusion: The prevalence results of this pilot study are in line with other observational studies of greater sample size for HIV indeterminate patients. Although the sample size is small, it suggests no elevated incidence of lung cancer in HIV heavy smokers. Although the rate of incident scanning is low, CT screening of HIV patients is feasible. This justifies accruing a larger sample of HIV patients perhaps from an already well defined, large, prospective cohort of HIV heavy smokers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3679. doi:10.1158/1538-7445.AM2011-3679
Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML
Authors: Maksim Klimiankou, Sabine Mellor-Heineke, Olga Klimenkova, Elisa Reinel, Murat Uenalan, Siarhei Kandabarau, Julia Skokowa, Karl Welte, Cornelia Zeidler
Journal: Blood (2016)
CN-13 * RECURRENT ASEPTIC MENINGITIS IN PATIENTS WITH METASTATIC BRAIN TUMORS; A NOVEL PERSPECTIVE
Authors: N. Majd, E. Neil, R. Warnick, J. Tew, R. Curry
Journal: Neuro-Oncology (2014)

Meningitis due to infectious or neoplastic infiltration is a commonly considered differential diagnosis in metastatic brain tumor patients presenting with altered mentation. However, aseptic meningitis, a disease marked by CSF pleocytosis, elevated protein, sterile cultures and negative cytology is rarely encountered. Aseptic meningitis has been described in benign CNS neoplasms that occur in the vicinity of ventricles, such as dermoid and epidermoid cysts. It has been postulated that rupture of a cystic CNS tumor nearby ventricles leads to leakage of neoplastic content into the CSF resulting in aseptic meningitis. A similar process has not been described in metastatic brain tumor patients. Here, we present a case of recurrent aseptic meningitis due to leakage of necrotic and neoplastic content into CSF in a patient with brain metastasis. 62 year old male presented with progressive aphasia 6 months after diagnosis of squamous cell lung cancer. Imaging revealed a left temporal lobe brain metastasis. Radiation therapy provided minimal improvement. Upon symptom progression, imaging favored radiation necrosis and bevacizumab was initiated with no improvement. On further deterioration, his CSF profile was consistent with aseptic meningitis with further spontaneous clinical improvement. He later presented with worsening symptoms and his repeat imaging showed enlargement of the previously noted left temporal mass with communication with the posterior temporal ventricle. A repeat CSF was consistent with recurrent aseptic meningitis. The patient underwent a left temporal craniotomy. The surgeon encountered liquid necrotic material at a depth of 5 mm and wide-open ventricles with easily discernable choroid plexus. Pathologic examination revealed mostly necrosis with some cancerous tissue. The patient continued to decline without recurrence of the meningitis and expired. This case signifies the importance of considering the leakage of necrotic tissue into subarachnoid space as the cause of recurrent aseptic meningitis in patients with cranial tumors close to the ventricles.
Abstract 2488: Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors
Authors: Valerie Sampson, Davida Kamara, Brian Calio, Edward A. Kolb
Journal: Cancer Research (2012)

Abstract Malignant peripheral nerve sheath tumors (MPNST) are a rare form of soft tissue sarcoma which may occur sporadically in the general population or in association with neurofibromatosis type 1 (NF1), and are highly aggressive and often fatal. NF1 patients are at a greater risk for the development of malignant peripheral nerve sheath tumors than the general population. Current therapy relies upon surgical resection with adjuvant chemotherapy and/or radiotherapy. Clinical trials using Reolysin (Respiratory Enteric Orphan Virus) which is developed from the naturally-occurring human reovirus have demonstrated the efficacy of this reovirus as an oncolytic virotherapy. Reolysin selectively replicates in cancer cells with activated Ras (Ras-GTP), resulting in virus-mediated apoptotic cell death. Hence Reolysin demonstrates promising anticancer activity and has minimal toxicity in patients. Since MPNST is associated with neurofibromin (NF1) deficiency and active Ras we tested these tumors as therapeutic targets for Reolysin treatment using two NF1 deficient human MPNST-derived cell lines (CRL-2884, ST8814) with activated Ras and one sporadic MPNST cell line (STS26T) which expresses NF1 but not active Ras. These were compared with normal human Schwann cells (NHSC) which do not show active Ras and mammary gland cells derived from an NF1 patient (CRL-7329). Reolysin inhibited the proliferation and viability of the three MPNST cell lines at a dose of 0.1 to 10 virus particles/cell, including sporadic MPNST cells which do not have active Ras. In contrast, the NHSC and CRL-7329 cells were more resistant to viral treatment, with apoptosis induced at higher viral concentrations (10,000 and 100,000 virus particles/cell respectively). Furthermore, we examined the effects of Reolysin on the Ras-signaling pathway in a bladder cancer cell line (HTB-4) expressing NF1 and Ras and found that virus induced cytotoxicity was similar to the control cell lines (100,000 virus particles/cell). This study shows that MPNST-derived cell lines including sporadic MPNST without active Ras were efficiently transduced, promoted virus replication and were killed by the oncolytic reovirus. In contrast to the highly sensitive MPNST cell lines, NHSC, CRL-7329 and HTB-4 cells were resistant at similar viral concentrations. Our data suggests the use of oncolytic Reolysin may represent a novel treatment approach for patients with MPNST and provides the basis for preclinical testing of the antitumor effects. Therapeutic efficacy of Reolysin in a mouse model for MPNST is underway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2488. doi:1538-7445.AM2012-2488
INITIAL MASKING OF ORGANIC BRAIN CHANGES BY PSYCHIC SYMPTOMS
Authors: R. W. WAGGONER, B. K. BAGCHI
Journal: American Journal of Psychiatry (1954)

Abbreviated case histories of 6 patients with brain tumor in whom mental symptoms were the first or important manifestation are presented. In these cases, the presence of a focal lesion was indicated by EEG before this was possible by initial clinical examination. [SEE SOURCE PDF FOR TABLE 1] It is recommended that, wherever possible or feasible, a routine EEG should be done on all mental hospital patients and that careful localizing electroencephalographic studies be done on all those in whom there is clinical or electroencephalographic suspicion of a focal lesion.
PTU-007 Evaluating Endoscopy Trainers; how Reliable Are Peer Evaluators?
Authors: L Macdougall, S Corbett, M Welfare, C Wells, J R Barton
Journal: Gut (2013)

<h3>Introduction</h3> The training of future endoscopists is important to ensure the ongoing provision of a safe endoscopy service within the UK; however endoscopy training is of a variable standard. Peer evaluation can be used to improve teaching but this does not currently routinely occur in local endoscopy units. We therefore wanted to assess the reliability of peer evaluations using an evaluation tool currently being developed to gain both trainee and peer evaluations. <h3>Methods</h3> The DOTS tool has been developed using the list of attributes described by Wells1. In order to gain an assessment of reliability the tool was trialled on JAG approved Training the Trainer courses. Courses from November to March 2012 were contacted and asked to participate. Each course attendant was then sent an information letter and consent form. On day two of the course participants were asked to complete a copy of the DOTS for each of the training episodes they observed. Data was analysed using SPSS 14; mean score and Cronbach alpha were calculated. Reliability was calculated using Generalisability theory; an initial analysis was performed using only trainers, peers and trainer: peer interaction as facets. A further analysis was then conducted including all possible sources of variance. <h3>Results</h3> Eight of the ten courses contacted agreed to participate; all course participants consented to the study. 189 evaluations were collected; these were completed by 58 different peers; 45 trainers were evaluated receiving from one to ten evaluations each. Mean total evaluation score was 63.3 (out of 85); standard deviation 8.6. The tool showed a high level of internal consistency with a Cronbach alpha of 0.895. In the initial analysis 44% of the variance of scores was explained by the difference in trainers' ability to teach, 35% due to peer variance and 21% by peer:trainer interaction. The G-coefficient for one rater was 0.44 and three raters were required for a G-coefficient of 0.7. When the analysis was repeated the effect of course accounted for 20% of the variance in scores. Reliability was much lower with a G coefficient of 0.28 for one rater. <h3>Conclusion</h3> The DOTS tool showed a high level of internal consistency. On initial analysis only three peer reviewers were required to gain acceptable levels of reliability. However on reanalysis the effect of course was responsible for the 20% of the variance and if results were generalised across course then the tool showed poor reliability. The effect of course was unexpected and needs to be investigated further; the tool also needs to be trialled within local units. <h3>Disclosure of Interest</h3> None Declared <h3>Reference</h3> Wells, C., <i>The characteristics of an excellent endoscopy trainer.</i> Frontline Gastroenterology, 2010. <b>1</b>: p. 13–18.
PMO-246 Urinary matrix metalloproteinases do not correlate with endoscopic or histological disease activity in ulcerative colitis
Authors: D S Pearl, S Edgar, M Whittaker, H Nitch-Smith, J F Brown, J K Shute, T M Trebble
Journal: Gut (2012)

<h3>Introduction</h3> Ulcerative colitis (UC) is a colonic inflammatory disorder of unconfirmed aetiology. Clinical assessment involves invasive endoscopic examination with a small yet significant procedural risk, on which therapeutic decisions are made. Non-invasive biomarkers may be better tolerated and reduce procedural costs and risks. Matrix metalloproteinases (MMP) are enzymes involved in tissue remodelling; MMP are elevated in mucosa and urine of children with active UC. We measured urinary MMP activity in adult patients with UC, matched controls investigated for functional symptoms and normal healthy volunteers to evaluate as a potential biomarker of disease activity. <h3>Methods</h3> Ethical approval and informed consent were obtained. Patients with UC and age-sex matched controls, identified during outpatient assessment, were prospectively recruited and flexible sigmoidoscopy (FS) performed. Endoscopic (Sutherland) and histological (Gomes) appearance in patients with UC was graded. A group of healthy volunteers were recruited at a local University. Urine samples, snap frozen at collection in liquid nitrogen, were thawed, centrifuged, and assayed using commercially obtained fluorescein-labelled gelatinase activity kits. MMP activity was corrected for creatinine concentration. Results were expressed as median ± IQR. Statistical tests included Kruskal–Wallis analysis and Spearman9s correlation. <h3>Results</h3> 80 active and 16 quiescent UC patients, 77 age-sex matched controls and 22 normal healthy volunteers were compared. Urinary MMP activity in active compared with quiescent UC (p=0.185) and in each compared with age-sex matched controls (p=0.237, p=0.525 respectively) was not significantly different. Exclusion of patients taking 5-aminosalicylates and corticosteroids did not alter significance. There was no correlation between urinary MMP activity and UC disease activity measured endoscopically (r=0.09, p=0.425) or histologically (r=0.178, p=0.127). Urinary MMP activity in healthy volunteers was significantly lower than patients with active UC (p&lt;0.0001), quiescent UC (p&lt;0.002), and controls (p&lt;0.0001). <h3>Conclusion</h3> Contrary to previously published work, our findings suggest that urinary MMP activity, measured using fluorescein-labelled gelatinase assay, does not discriminate between quiescent and active UC and does not correlate with UC disease activity. Significant differences noted between healthy volunteers and patients with UC were unexpected, but may reflect difference in group demographics. MMP gelatinase assays are therefore a poor non-invasive biomarker of disease activity in UC. <h3>Competing interests</h3> None declared.
P30 * IS NATIONAL SURGEON LEVEL DATA ACCURATE?
Authors: A. Alqallaf, A. R. Brodbelt, D. Greenberg, T. Winters, M. Williams, S. Vernon, J. Flowers, P. Collins
Journal: Neuro-Oncology (2014)

INTRODUCTION: Publication of surgeon level outcome data occurs with cardiac and vascular surgeons. Neurosurgeons treating patients with tumours can expect to have their data published within the next 12 months. It is important that data is accurate. We wished to compare a search from the national database for patients with Glioblastoma Multiforme (GBM) to the figures obtained from a local investigation of the data for a single surgeon. METHOD: A search strategy encompassing all patients with a GBM treated between 2007-2010 was obtained from data linkage between Encore (National Cancer Registration service), and HES (Hospital episode statistics). This was compared with a retrospective data collection for the same time frame for a single surgeon from hospital databases at our centre. RESULTS: The national search suggested 23 patients were treated by the single surgeon with debulking and Stupp, and had a median life expectancy of 10.5 months. Hospital data suggested that 123 patients were treated over the same period of time, 92 of them from England. Of the English patients, 43 were debulked, and 49 had a biopsy. Age range 19-82. Median life expectancies for debulking patients was 11 months overall, or 9 months for English patients, and only 5 months for English patients having a biopsy. CONCLUSION: Surgeons are naturally concerned that surgeon level data may be inaccurate. Surgeons must take responsibility for checking and recording data to ensure national outcome data attributed to them is accurate.
Abstract 1816: SULT1A1 gene expression level is correlated with gene copy number in different human epithelial and breast cancer cell lines.
Authors: Aiwei Yao-Borengasser, Lora J. Rogers, Rosalind B. Penny, Vineetha K. Edvana, Susan A. Kadlubar
Journal: Cancer Research (2013)

Abstract Sulfotransferase isoform 1A1 (SULT1A1) is a member of a subfamily of cytosolic enzymes which catalyze the transfer of a sulfonate group from 3’-phosphoadenosine 5’ -phosphosulfate (PAPS) to a range of xenobiotic and endogenous compounds such as drugs, carcinogens, and steroid hormones. SULT1A1 plays a role in detoxification of tamoxifen (TAM), a drug for estrogen receptor (ER) positive breast cancer treatment and chemoprevention. Besides its involvement in drug metabolism, SULT1A1 also contributes to increased cancer risk. SULT1A1 activity varies several-fold among individuals. Earlier studies have shown that individuals can possess one to five copies of the SULT1A1 gene. SULT1A1 gene expression is higher in individuals with more than one copy number, although there is no significant difference among individuals who have more than 3 copy numbers. We determined the copy number of SULT1A1 in cell lines ZR75, MCF7, T47D, MDA-MB-231, and MCF10A using a pre-designed Custom Plus TaqMan® Copy Number kit from Life Technology. Similar to the human population, the human cell lines tested also contain one to five copies of SULT1A1. Genomic DNA of MCF7, MDA-MB-231, and MCF10A cells contains only one copy of SULT1A1, while ZR75 DNA contains 3 copies and T47D DNA contains 5 copies of SULT1A1. To determine if copy number correlates with gene expression level, we compared the amount of SULT1A1 mRNA by RT-PCR in each cell line with corresponding copy numbers. Cell lines with one copy of SULT1A1 (MCF7 and MCF10A) had lower gene expression; while cell lines with more than one copy number (ZR75 and T47D) had higher gene expression. ZR75 cells expressed significantly more SULT1A1 mRNA than that of T47D, even though ZR75 DNA has two less copies than T47D cells. Although MDA-MB-231 DNA contains one copy of SULT1A1, no SULT1A1 gene expression was detected, indicating that other mechanisms exist in regulating SULT1A1 gene expression. In summary, the current data suggest that differential SULT1A1 gene expression levels in human breast cancer cells could be partially regulated by its copy numbers. Furthermore, the cell lines tested here could be used as in vitro models to study the mechanisms of SULT1A1 gene expression regulations since the copy number differences in those cell lines represented the copy number differences in human population. Citation Format: Aiwei Yao-Borengasser, Lora J. Rogers, Rosalind B. Penny, Vineetha K. Edvana, Susan A. Kadlubar. SULT1A1 gene expression level is correlated with gene copy number in different human epithelial and breast cancer cell lines. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1816. doi:10.1158/1538-7445.AM2013-1816
The Problem of Nutrition in the Postoperative Care of Abdominal Wounds of Warfare
Authors: J. E. Dunphy, Stanley O. Hoerr, C. L. Dimmler, Robert R. White
Journal: New England Journal of Medicine (1946)

RAPID evacuation, the improved treatment of shock and skilled surgery available within a few miles of the front have made it possible to operate on many patients with abdominal wounds of an extent and gravity seldom seen in those treated in World War I. Despite this fact, the immediate postoperative mortality of 5O per cent, generally accepted as representative of the last war,1 has been considerably reduced.2 , 3 Most reports of experiences in this field have dealt largely with the operative and immediate postoperative periods. The complex problems in nutrition and sepsis presented by some of these patients on arrival at . . .